谷歌浏览器插件
订阅小程序
在清言上使用

Dosimetry of 177Lu-DOTATOC first circle treatment in patients with advanced metastatic neuroendocrine tumors: A pilot study in China

Applied Radiation and Isotopes(2022)

引用 1|浏览32
暂无评分
摘要
First cycle dosimetry calculation of Lu-177-DOTATOC (single activity:1.59-3.49 GBq) was carried out in eight patients with advanced neuroendocrine tumors (NETs) who underwent whole-body planar (0.5, 24, 48, 72 h) and SPECT/CT scans (24 h). Focal uptake of Lu-177-DOTATOC was found in primary and metastatic tumors. Organs with the highest absorbed doses per injected activity were tumors (1.293 +/- 0.862 mGy/MBq) and spleen (0.461 +/- 0.408 mGy/MBq), while low absorbed doses were observed in kidneys (0.384 +/- 0.112 mGy/MBq) and bone marrow (0.0297 +/- 0.0123 mGy/MBq). Lu-177-DOTATOC is safe, well-tolerated and appropriate in Chinese NETs patients for PRRT.
更多
查看译文
关键词
Lu-177-DOTATOC,PRRT,Dosimetry,Neuroendocrine tumor
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要